AngioDynamics anticipates $336M-$341M FY 2027 net sales while targeting $13M-$16M adjusted EBITDA (NASDAQ:ANGO)

AngioDynamics (ANGO) issued forward guidance for FY2027 projecting net sales of $336M–$341M alongside adjusted EBITDA targets of $13M–$16M, representing management's confidence in multiple product line trajectories. The guidance emerged from Q4 FY2026 earnings commentary highlighting three operational drivers: NanoKnife momentum, Auryon thrombectomy platform expansion, and downstream catalysts in the interventional oncology and vascular intervention segments.

The revenue guidance implies modest year-over-year growth from current run-rates, signaling stabilization in core franchises rather than explosive expansion. The EBITDA range, however, reflects margin pressure—suggesting cost structure challenges or near-term investment spending to support product adoption. Management appears to be balancing growth investments against profitability, typical of mid-cap medical device firms transitioning through product lifecycle stages.

Product-specific catalysts (NanoKnife irreversible electroporation and Auryon mechanical thrombectomy) represent the primary upside drivers for the stock, as these therapies address high-margin interventional markets. Thrombectomy particularly benefits from aging demographics and stroke prevalence trends, while oncology applications expand addressable market depth. Execution risk remains elevated—clinical adoption rates and reimbursement dynamics will determine whether guidance reflects sustainable growth or cyclical uplift.

Sector implication: The guidance reflects measured optimism in specialty medical devices, a segment benefiting from procedural volume recovery post-pandemic and expanding indications. ANGO's trajectory will serve as a barometer for mid-cap innovation-driven medtech valuations within the Health Care sector.